Developing in vivo CAR T-cell therapies requires reliable approaches for transient, controlled CAR expression and targeted mRNA delivery to immune cells. This webinar will examine the transformative role of mRNA and lipid nanoparticle (LNP) technologies in advancing in vivo CAR T-cell therapy, including practical considerations for platform selection and optimization.
The featured speakers will explore the foundational principles of mRNA-based CAR T development, focusing on how mRNA enables transient yet precise expression of therapeutic CAR constructs. Additionally, they will discuss the critical role of LNPs in ensuring efficient and targeted delivery of mRNA to immune cells in vivo.
The webinar will also highlight how end-to-end capabilities across mRNA synthesis, LNP formulation development and analytical testing can support optimization for in vivo CAR T applications, with examples of common development challenges and decision points. Attendees will gain valuable insights into the latest innovations in mRNA and LNP technology and how they are shaping the future of CAR T-cell therapy.
Register for this webinar to learn how LNP technology can support in vivo CAR-T development through effective mRNA delivery and analytical readiness.
Speaker
Juliana Campo Garcia, Field Application Scientist, GenScript Biotech
Juliana Campo Garcia has a background in neurobiology and immunology, where she focused on characterizing regenerative niches in the adult brain and on investigating the effects of invading immune cells on neural stem cells.
Since joining GenScript as a Field Application Scientist, she has specialized in RNA and CRISPR technologies, expanding her expertise to provide expert technical support to customers.
Message PresenterWho Should Attend?
This webinar will appeal to:
- Scientists and R&D leads working on mRNA-based therapeutics
- Molecular biology researchers focused on IVT mRNA production
- RNA therapeutics teams exploring scale-up and IND readiness
- Biotech professionals in vaccine, gene and cell therapy development
What You Will Learn
Attendees will:
- Understand the fundamental principles of mRNA and LNP technology and their unique advantages for in vivo CAR T-cell development
- Learn how mRNA synthesis, LNP formulation and analytical testing support platform optimization
- Discover the latest advancements in mRNA and LNP-based CAR T therapies and how they are paving the way for groundbreaking immuno-oncology treatments
Xtalks Partner
GenScript
GenScript is the leading contract research organization in the world providing gene, peptide, protein, CRISPR, and antibody. Since its foundation in 2002, GenScript has grown exponentially through partnerships with scientists conducting fundamental life science research, translational biomedical research, and early stage pharmaceutical development. The company is recognized as having built a best-in-class capacity and capability for biological research services, encompassing gene synthesis, peptide synthesis, custom antibody and protein engineering, and in vitro and in vivo pharmacology – all with the goal to make people and nature healthier through biotechnology by scripting possibilities.
You Must Login To Register for this Free Webinar
Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.
Create Account